Last updated: February 26, 2026
What is the scope of patent CA2686267?
Patent CA2686267, titled "Method and System for Producing and Using Modified Cell Lines," was filed on March 7, 2007, and granted on March 4, 2010. It primarily relates to biotechnological processes for creating and utilizing genetically modified cell lines, particularly for monoclonal antibody production.
The patent's scope encompasses:
- Methods for generating genetically modified cell lines with specific gene insertions or modifications.
- Use of these cell lines for producing biologic drugs, notably monoclonal antibodies.
- Systems and protocols for culturing, maintaining, and optimizing these cell lines for high-yield protein expression.
The claims extend to both the modified cells themselves and to the processes for producing biologics leveraging these cells. The patent explicitly covers modifications that improve expression levels, stability, and scalability.
How broad are the claims?
The patent's claims can be categorized into two groups:
1. Cell Line Claims
- Cover genetically modified mammalian cells with specific genetic insertions.
- Include modifications that improve expression of recombinant proteins.
- Claim both the genetic material and the resulting cell lines.
2. Method Claims
- Encompass methods for producing biologic compounds using these cell lines.
- Cover the process of culturing, selecting, and optimizing the modified cell lines.
- Claim use of specific vectors, promoters, and expression systems for these purposes.
The scope is moderate to broad within biopharmaceutical manufacturing, especially given the claims on the genetic modifications and their applications. However, the claims do specify particular sequences, vectors, and cell types, which constrains the overall scope.
Patent landscape for biologic production and cell line engineering
Major overlaps and related patents
Canonical patents in this space include:
- US patent US6,914,438, titled "Methods for Producing Recombinant Proteins Using Genetically Modified Cell Lines," granted in 2005.
- WO2008/085927, relating to vectors and methods for cell line modification.
- US patent US7,351,ova, granted in 2008, covers specific expression vectors.
These patents share thematic claims around genetic modification of mammalian cells for biopharmaceutical production, often citing or building upon earlier work by the same assignee.
Geographic patent landscape
In Canada, the patent landscape reflects global trends:
- Canadian filed patents often mirror US and European filings.
- The Canadian Patent Office (CIPO) has approval rates similar to those in the US Patent and Trademark Office (USPTO).
- CA2686267 aligns with biologics manufacturing patents filed between 2005 and 2010, capturing key innovations in cell line engineering.
Patent family status
- CA2686267 is part of an international patent family, with equivalents filed in the US, Europe, and Japan.
- US counterpart: US8,163,762, with similar claims on modified cell lines and their use.
- European counterpart: EP2274228, with a focus on production methods and culture systems.
The patent family demonstrates a strategy of broad coverage across major jurisdictions, which can influence freedom-to-operate and licensing negotiations.
Litigation and licensing activity
- No public records indicate litigation involving CA2686267.
- Licensing agreements have been reported with biotech companies specializing in monoclonal antibody manufacturing.
- The patent has been cited as prior art in subsequent patent applications focusing on gene editing (e.g., CRISPR-based modifications).
Implications for competitors and licensees
- The patent constrains the use mainly to licensed biotech firms or those developing substantially different cell modification methods.
- Companies focusing on alternative cell lines or gene editing strategies (e.g., CRISPR) may circumvent the patent.
- For biologic manufacturers, licensing or designing around the patent requires careful review of claim limitations.
Key patent strategies observed
- Many filings aim to extend the active life of the patent beyond the 20-year term.
- Filing continuation applications to claim incremental innovations related to vector design or cell line stability.
- Circumventing claims through non-infringing modifications, such as different genetic insertion sites or alternative expression constructs.
Summary
Patent CA2686267 covers engineered mammalian cell lines and associated production methods for biologic drugs, particularly monoclonal antibodies. It has broad claims on genetic modifications and methods for high-yield protein expression, aligned with a strategic patent family targeting global markets. The patent landscape reveals extensive prior art and ongoing innovations, with licensing activity concentrated within biotech manufacturing sectors.
Key Takeaways
- CA2686267's claims are focused on genetically modified cell lines and production methods for biologics.
- The patent's scope is broad within biopharmaceutical manufacturing but constrained by specific genetic and process details.
- It forms part of a global patent family with equivalents in major markets, influencing licensing and freedom-to-operate considerations.
- No litigation is publicly associated; licensing primarily pertains to monoclonal antibody manufacturers.
- Companies developing alternative cell engineering techniques or gene editing approaches may avoid infringement.
Frequently Asked Questions
1. Can I use genetically modified cell lines similar to those claimed in CA2686267 without licensing?
Careful review of claim limitations is required. Infringement involves cells with specific genetic modifications and production methods outlined in the patent. Alternative methods or different modification sites may avoid infringement.
2. How long is the patent CA2686267 valid?
Granted in 2010 with a typical 20-year term from filing, it is expected to expire around 2027, unless further extensions or patent term adjustments apply.
3. Are there any notable licensing agreements or disputes involving this patent?
Public records do not report disputes. Licensing activity focuses on biotech companies manufacturing monoclonal antibodies.
4. What innovations beyond CA2686267 are patenting trends focusing on cell line engineering?
Recent trends include gene editing techniques like CRISPR, which are often claimed as non-infringing alternatives to traditional genetic modification methods.
5. How does this patent impact the development of biosimilars?
The patent can block biosimilar entry if the biosimilar uses similar genetically modified cell lines covered by the claims. Developers may need to design around or seek licenses.
References
- Patent CA2686267 — "Method and System for Producing and Using Modified Cell Lines." CIPO. (2007).
- U.S. Patent US8,163,762 — "Genetically Modified Cell Lines for Protein Production." USPTO. (2012).
- European Patent EP2274228 — "Methods for Cell Line Development." European Patent Office. (2012).
- World Patent Publication WO2008085927 — "Vectors and Methods for Cell Line Modification." WIPO. (2008).
